Watch Cerba Research’s latest webinar, ‘The Added Value of Flow Cytometry in CAR T-Cell Clinical Trials’.
HISTOSELECT: How to Overcome Challenges in Antibody Selection?
HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).
Reach out to our experts and discover how we can help you advance your researchContact Us
Flow Cytometry Advantages in Immunotherapy Clinical Trials
More than three decades ago, scientists at the National Cancer Institute began exploring ways to fight cancer using the patient’s immune system. Their work formed the basis of what is now a promising cancer treatment that doesn’t require surgery or radiation. The global immunotherapy market as well as cell and gene therapy, such as CAR T, adoptive cell therapies, checkpoint inhibitors and other immunotherapies, is expected to grow by 10.1% CAGR between 2020 and 2028.
Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. Each sample they give is precious, as they all provide a wealth of biological data that contributes to therapy development. To ensure samples arrive at the lab intact, robust sample transportation and global logistics are critical. The deep scientific expertise housed within those labs ensures the highest-quality analysis and reporting.
Our white paper takes an in-depth look at the world of flow cytometry. Nithianandan Selliah, Global Head of Flow Cytometry, and collaborators at Cerba Research, examine its unique benefits and future potential. They highlight the latest trends in technology and set out the key points to consider when planning a flow cytometry-based clinical trial and choosing a partner lab.
White Paper – Flow Cytometry advantages in Immunotherapy Clinical Trials
Reach out to our experts to discover how we can advance your clinical trial with Flow CytometryContact Us